Benign prostatic hyperplasia is the most common urological disease in men.
Significant factors that make difficult and burdensome surgery, patients are advanced age and the presence of comorbid conditions. Therefore, along with the improvement of operative technique, special attention is always paid to the pharmacotherapy of benign prostatic hyperplasia.
Drug treatment is not effective in all patients but it is almost never able to prevent an emergency surgery shown. However, in most cases, medicines can significantly improve the functional performance of urination and reduce the impact of disease on quality of life.
Among many groups of drugs previously used for the treatment of patients with benign prostatic hyperplasia only a1-blockers, inhibitors of 5a-reductase and some herbal remedies proved to be effective.
Blockers are most often used in clinical practice. This is due to several reasons. First, they are effective. The pharmacological properties of these drugs are well studied and have a level of evidence A (highest), which means that the validity of the recommendations previously conducted randomized controlled trials. Second, the drugs this group have a low toxicity and good tolerability. The third advantage of a-blockers is a relatively rapid onset of action is 2-4 weeks. For comparison, the effect of inhibitors of 5a-reductase occurs after an average of 6 months of continuous administration.
Currently, the US market has the following representatives of pharmacological alfuzosin, doxazosin, tamsulosin, terazosin. The differences between the drugs are in the expression of their therapeutic effects on the prostate and bladder neck, and in their pharmacodynamic and pharmacokinetic characteristics.